The abstract is read at the publisher; the summary is JClub's.
β-catenin, encoded by CTNNB1, is part of a major WNT oncogenic axis present in approximately 10% of human cancers, making it a prime precision oncology target.
- Why it matters: The WNT/β-catenin pathway is strongly linked to cancer initiation, progression, and maintenance, yet upstream blockade and conventional β-catenin targeting have largely failed, leaving major unmet needs.
- What they did: This review summarizes decades of pathway biology and evaluates therapeutic strategies that directly target β-catenin, including disrupting its interactions with T-cell factor proteins or inducing β-catenin degradation.
- The result: Recent novel approaches are highlighted as making β-catenin targeting—previously considered “undruggable”—increasingly achievable, with potential impact for hard-to-treat cancers such as colorectal cancer and hepatocellular carcinoma.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.